Relay Therapeutics (RLAY) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary

Portfolio and development priorities

• RLY-2608 is a PI3Kα mutant selective inhibitor with three ongoing trials, including a pivotal post-CDK4/6 metastatic breast cancer trial started this summer.

• Preparing for frontline metastatic strategies with triplet combinations and advancing a vascular malformations trial.

• Preclinical assets in KRAS and NRAS are in development, with cash runway into 2029.

Clinical profile and competitive positioning

• RLY-2608 shows improved selectivity, reducing toxicities and enabling higher dose intensity and longer treatment duration.

• Demonstrated double-digit PFS in second-line breast cancer, surpassing capivasertib's 5.5 months.

• Capivasertib chosen as control arm due to its current standard-of-care status despite lower PFS than alpelisib.

• Confident in exceeding the PFS benchmark set by capivasertib.

• RLY-2608 shows a 39% confirmed response rate, outperforming Scorpion Lilly's 20% and other early generation molecules.

Mutation coverage and trial strategy

• RLY-2608 demonstrates activity across all PI3Kα mutations, with higher selectivity for helical mutations compared to competitors.

• Ongoing trials are designed to address both kinase and helical mutation subgroups.